177 related articles for article (PubMed ID: 8301198)
1. High-density lipoprotein inhibits the production of platelet activating factor acetylhydrolase by HepG2 cells.
Satoh K; Imaizumi T; Yoshida H; Takamatsu S
J Lab Clin Med; 1994 Feb; 123(2):225-31. PubMed ID: 8301198
[TBL] [Abstract][Full Text] [Related]
2. Platelet-activating factor (PAF) stimulates the production of PAF acetylhydrolase by the human hepatoma cell line, HepG2.
Satoh K; Imaizumi T; Kawamura Y; Yoshida H; Hiramoto M; Takamatsu S; Takamatsu M
J Clin Invest; 1991 Feb; 87(2):476-81. PubMed ID: 1846878
[TBL] [Abstract][Full Text] [Related]
3. Effect of 17 beta-estradiol on secretion of platelet-activating factor acetylhydrolase by HepG2 cells.
Satoh K; Imaizumi T; Yoshida H; Takamatsu S
Metabolism; 1993 Jun; 42(6):672-7. PubMed ID: 8510509
[TBL] [Abstract][Full Text] [Related]
4. Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma.
Stafforini DM; Carter ME; Zimmerman GA; McIntyre TM; Prescott SM
Proc Natl Acad Sci U S A; 1989 Apr; 86(7):2393-7. PubMed ID: 2928339
[TBL] [Abstract][Full Text] [Related]
5. Liver cells secrete the plasma form of platelet-activating factor acetylhydrolase.
Tarbet EB; Stafforini DM; Elstad MR; Zimmerman GA; McIntyre TM; Prescott SM
J Biol Chem; 1991 Sep; 266(25):16667-73. PubMed ID: 1653245
[TBL] [Abstract][Full Text] [Related]
6. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor.
Stafforini DM; McIntyre TM; Carter ME; Prescott SM
J Biol Chem; 1987 Mar; 262(9):4215-22. PubMed ID: 3549727
[TBL] [Abstract][Full Text] [Related]
7. PAF-acetylhydrolase, predominantly present in LDL in healthy subjects, is associated with HDL in a patient with LDL deficiency.
Surya II; Mommersteeg M; Erkelens DW; Akkerman JW
J Lipid Mediat; 1991; 3(1):27-38. PubMed ID: 1768838
[TBL] [Abstract][Full Text] [Related]
8. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme.
Tselepis AD; Dentan C; Karabina SA; Chapman MJ; Ninio E
Arterioscler Thromb Vasc Biol; 1995 Oct; 15(10):1764-73. PubMed ID: 7583554
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein.
Stafforini DM; Tjoelker LW; McCormick SP; Vaitkus D; McIntyre TM; Gray PW; Young SG; Prescott SM
J Biol Chem; 1999 Mar; 274(11):7018-24. PubMed ID: 10066756
[TBL] [Abstract][Full Text] [Related]
10. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress.
Noto H; Hara M; Karasawa K; Iso-O N; Satoh H; Togo M; Hashimoto Y; Yamada Y; Kosaka T; Kawamura M; Kimura S; Tsukamoto K
Arterioscler Thromb Vasc Biol; 2003 May; 23(5):829-35. PubMed ID: 12649088
[TBL] [Abstract][Full Text] [Related]
11. Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase. Comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis.
De Geest B; Stengel D; Landeloos M; Lox M; Le Gat L; Collen D; Holvoet P; Ninio E
Arterioscler Thromb Vasc Biol; 2000 Oct; 20(10):E68-75. PubMed ID: 11031226
[TBL] [Abstract][Full Text] [Related]
12. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein.
Watson AD; Navab M; Hama SY; Sevanian A; Prescott SM; Stafforini DM; McIntyre TM; Du BN; Fogelman AM; Berliner JA
J Clin Invest; 1995 Feb; 95(2):774-82. PubMed ID: 7860760
[TBL] [Abstract][Full Text] [Related]
13. Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect.
Milionis HJ; Tambaki AP; Kanioglou CN; Elisaf MS; Tselepis AD; Tsatsoulis A
Thyroid; 2005 May; 15(5):455-60. PubMed ID: 15929667
[TBL] [Abstract][Full Text] [Related]
14. Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on paraoxonase and platelet-activating factor acetylhydrolase in human plasma and tissue fluid.
Kujiraoka T; Hattori H; Ito M; Nanjee MN; Ishihara M; Nagano M; Iwasaki T; Cooke CJ; Olszewski WL; Stepanova IP; Egashira T; Miller NE
Atherosclerosis; 2004 Sep; 176(1):57-62. PubMed ID: 15306175
[TBL] [Abstract][Full Text] [Related]
15. Dissociable and nondissociable forms of platelet-activating factor acetylhydrolase in human plasma LDL: implications for LDL oxidative susceptibility.
McCall MR; La Belle M; Forte TM; Krauss RM; Takanami Y; Tribble DL
Biochim Biophys Acta; 1999 Jan; 1437(1):23-36. PubMed ID: 9931415
[TBL] [Abstract][Full Text] [Related]
16. Release of platelet-activating factor in systemic lupus erythematosus.
Tetta C; Bussolino F; Modena V; Montrucchio G; Segoloni G; Pescarmona G; Camussi G
Int Arch Allergy Appl Immunol; 1990; 91(3):244-56. PubMed ID: 2354868
[TBL] [Abstract][Full Text] [Related]
17. Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor.
Ambrosio G; Oriente A; Napoli C; Palumbo G; Chiariello P; Marone G; Condorelli M; Chiariello M; Triggiani M
J Clin Invest; 1994 Jun; 93(6):2408-16. PubMed ID: 8200975
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.
Tsimihodimos V; Karabina SA; Tambaki AP; Bairaktari E; Goudevenos JA; Chapman MJ; Elisaf M; Tselepis AD
Arterioscler Thromb Vasc Biol; 2002 Feb; 22(2):306-11. PubMed ID: 11834533
[TBL] [Abstract][Full Text] [Related]
19. PAF-acether-degrading acetylhydrolase in plasma LDL is inactivated by copper- and cell-mediated oxidation.
Dentan C; Lesnik P; Chapman MJ; Ninio E
Arterioscler Thromb; 1994 Mar; 14(3):353-60. PubMed ID: 8123638
[TBL] [Abstract][Full Text] [Related]
20. The contribution of individual lipoproteins to the degradation of platelet-activating factor in human serum.
Ostermann G; Kostner GM; Gries A; Malle E; Till U
Haemostasis; 1989; 19(3):160-8. PubMed ID: 2744632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
